135 related articles for article (PubMed ID: 37790427)
1.
Dureja C; Rutherford JT; Pavel FBA; Norseeda K; Prah I; Sun D; Hevener KE; Hurdle JG
bioRxiv; 2023 Sep; ():. PubMed ID: 37790427
[No Abstract] [Full Text] [Related]
2.
Dureja C; Rutherford JT; Pavel FB; Norseeda K; Prah I; Sun D; Hevener KE; Hurdle JG
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0122223. PubMed ID: 38265216
[No Abstract] [Full Text] [Related]
3. The Fatty Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum Antibacterials for Clostridium difficile Infection.
Marreddy RKR; Wu X; Sapkota M; Prior AM; Jones JA; Sun D; Hevener KE; Hurdle JG
ACS Infect Dis; 2019 Feb; 5(2):208-217. PubMed ID: 30501172
[TBL] [Abstract][Full Text] [Related]
4. Small-Molecule Inhibition of the
Jones JA; Prior AM; Marreddy RKR; Wahrmund RD; Hurdle JG; Sun D; Hevener KE
ACS Chem Biol; 2019 Jul; 14(7):1528-1535. PubMed ID: 31184849
[No Abstract] [Full Text] [Related]
5. Biophysical library screening using a Thermo-FMN assay to identify and characterize Clostridioides difficile FabK inhibitors.
Pavel FBA; Palmer GE; Hevener KE
Biochem Biophys Res Commun; 2024 Apr; 705():149740. PubMed ID: 38458032
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of phenylimidazole FabK inhibitors as new Anti-C. Difficile agents.
Norseeda K; Bin Aziz Pavel F; Rutherford JT; Meer HN; Dureja C; Hurdle JG; Hevener KE; Sun D
Bioorg Med Chem; 2023 Jun; 88-89():117330. PubMed ID: 37224699
[TBL] [Abstract][Full Text] [Related]
7. The
Wickramage I; Peng Z; Chakraborty S; Harmanus C; Kuijper EJ; Alrabaa S; Smits WK; Sun X
Microbiol Spectr; 2023 Jun; 11(3):e0377722. PubMed ID: 37125917
[TBL] [Abstract][Full Text] [Related]
8. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
Collins DA; Riley TV
Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
[TBL] [Abstract][Full Text] [Related]
9. Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against
Murphy CK; O'Donnell MM; Hegarty JW; Schulz S; Hill C; Ross RP; Rea MC; Farquhar R; Chesnel L
World J Gastrointest Pathophysiol; 2023 Aug; 14(4):71-85. PubMed ID: 37727283
[TBL] [Abstract][Full Text] [Related]
10. [Clostridioides difficile - New Insights and Therapy Recommendations].
Schönherr S; Jung L; Lübbert C
Dtsch Med Wochenschr; 2023 Jun; 148(12):752-758. PubMed ID: 37257477
[TBL] [Abstract][Full Text] [Related]
11. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
[No Abstract] [Full Text] [Related]
12. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
Nelson RL; Suda KJ; Evans CT
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
[TBL] [Abstract][Full Text] [Related]
13. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.
Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD
mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161
[TBL] [Abstract][Full Text] [Related]
14. An Aniline-Substituted Bile Salt Analog Protects both Mice and Hamsters from Multiple Clostridioides difficile Strains.
Phan JR; Do DM; Truong MC; Ngo C; Phan JH; Sharma SK; Schilke A; Mefferd CC; Villarama JV; Lai D; Consul A; Hedlund BP; Firestine SM; Abel-Santos E
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0143521. PubMed ID: 34780262
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of
Rutherford JT; Avad K; Dureja C; Norseeda K; Gc B; Wu C; Sun D; Hevener KE; Hurdle JG
ACS Infect Dis; 2024 May; 10(5):1612-1623. PubMed ID: 38597503
[No Abstract] [Full Text] [Related]
16. Antimicrobial Activity of Tannic Acid
Wang W; Cao J; Yang J; Niu X; Liu X; Zhai Y; Qiang C; Niu Y; Li Z; Dong N; Wen B; Ouyang Z; Zhang Y; Li J; Zhao M; Zhao J
Microbiol Spectr; 2023 Feb; 11(1):e0261822. PubMed ID: 36537806
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiota in burned patients with Clostridioides difficile infection.
Shoaei P; Shojaei H; Siadat SD; Moshiri A; Vakili B; Yadegari S; Ataei B; Khorvash F
Burns; 2022 Aug; 48(5):1120-1129. PubMed ID: 34924229
[TBL] [Abstract][Full Text] [Related]
18. Intestinal Inflammation Reversibly Alters the Microbiota to Drive Susceptibility to Clostridioides difficile Colonization in a Mouse Model of Colitis.
Barron MR; Sovacool KL; Abernathy-Close L; Vendrov KC; Standke AK; Bergin IL; Schloss PD; Young VB
mBio; 2022 Aug; 13(4):e0190422. PubMed ID: 35900107
[TBL] [Abstract][Full Text] [Related]
19. Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?
Krutova M; Wilcox M; Kuijper E
Int J Infect Dis; 2022 Nov; 124():118-123. PubMed ID: 36155825
[TBL] [Abstract][Full Text] [Related]
20. Exploring novel microbial metabolites and drugs for inhibiting
Abouelkhair AA; Seleem MN
mSphere; 2024 Jun; ():e0027324. PubMed ID: 38940508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
